103 related articles for article (PubMed ID: 38609433)
1. Reprint of: The Diagnostic and Prognostic Utility of Incorporating DAXX, ATRX, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of Pancreatic Neuroendocrine Tumors (PanNETs).
Heaphy CM; Singhi AD
Hum Pathol; 2023 Feb; 132():1-11. PubMed ID: 36702689
[TBL] [Abstract][Full Text] [Related]
2. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
Umetsu SE; Kakar S; Basturk O; Kim GE; Chatterjee D; Wen KW; Hale G; Shafizadeh N; Cho SJ; Whitman J; Gill RM; Jones KD; Navale P; Bergsland E; Klimstra D; Joseph NM
Mod Pathol; 2023 Mar; 36(3):100065. PubMed ID: 36788102
[TBL] [Abstract][Full Text] [Related]
3. Combined deletion of MEN1, ATRX and PTEN triggers development of high-grade pancreatic neuroendocrine tumors in mice.
Fuentes ME; Lu X; Flores NM; Hausmann S; Mazur PK
Sci Rep; 2024 Apr; 14(1):8510. PubMed ID: 38609433
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors.
Uemura J; Okano K; Oshima M; Suto H; Ando Y; Kumamoto K; Kadota K; Ichihara S; Kokudo Y; Maeba T; Nanno Y; Toyama H; Takada Y; Shimada M; Hanazaki K; Masaki T; Suzuki Y
Ann Surg; 2021 Dec; 274(6):e949-e956. PubMed ID: 31599805
[TBL] [Abstract][Full Text] [Related]
5. Two well-differentiated pancreatic neuroendocrine tumor mouse models.
Wong C; Tang LH; Davidson C; Vosburgh E; Chen W; Foran DJ; Notterman DA; Levine AJ; Xu EY
Cell Death Differ; 2020 Jan; 27(1):269-283. PubMed ID: 31160716
[TBL] [Abstract][Full Text] [Related]
6. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.
Park JK; Paik WH; Lee K; Ryu JK; Lee SH; Kim YT
Oncotarget; 2017 Jul; 8(30):49796-49806. PubMed ID: 28591701
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of Altered ATRX/DAXX Gene in Pancreatic Neuroendocrine Tumors: A Meta-Analysis.
Wang F; Xu X; Ye Z; Qin Y; Yu X; Ji S
Front Endocrinol (Lausanne); 2021; 12():691557. PubMed ID: 34220718
[TBL] [Abstract][Full Text] [Related]
8. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.
Singhi AD; Liu TC; Roncaioli JL; Cao D; Zeh HJ; Zureikat AH; Tsung A; Marsh JW; Lee KK; Hogg ME; Bahary N; Brand RE; McGrath KM; Slivka A; Cressman KL; Fuhrer K; O'Sullivan RJ
Clin Cancer Res; 2017 Jan; 23(2):600-609. PubMed ID: 27407094
[TBL] [Abstract][Full Text] [Related]
9. Menin-KMT2A interaction inhibitor shows promise.
Killock D
Nat Rev Clin Oncol; 2023 May; 20(5):284. PubMed ID: 36991259
[No Abstract] [Full Text] [Related]
10. ATRX, a guardian of chromatin.
Aguilera P; López-Contreras AJ
Trends Genet; 2023 Jun; 39(6):505-519. PubMed ID: 36894374
[TBL] [Abstract][Full Text] [Related]
11. Metastatic pancreatic neuroendocrine tumors feature elevated T cell infiltration.
Greenberg J; Limberg J; Verma A; Kim D; Chen X; Lee YJ; Moore MD; Ullmann TM; Thiesmeyer JW; Loewenstein Z; Chen KJ; Egan CE; Stefanova D; Bareja R; Zarnegar R; Finnerty BM; Scognamiglio T; Du YN; Elemento O; Fahey TJ; Min IM
JCI Insight; 2022 Dec; 7(23):. PubMed ID: 36301668
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of an Atrx Conditional Knockout Mouse Model: Atrx Loss Causes Endocrine Dysfunction Rather Than Pancreatic Neuroendocrine Tumour.
Gaspar TB; Macedo S; Sá A; Soares MA; Rodrigues DF; Sousa M; Mendes N; Martins RS; Cardoso L; Borges I; Canberk S; Gärtner F; Miranda-Alves L; Sobrinho-Simões M; Lopes JM; Soares P; Vinagre J
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010860
[TBL] [Abstract][Full Text] [Related]
13. Context matters - Daxx and Atrx are not robust tumor suppressors in the murine endocrine pancreas.
Sun C; Estrella JS; Whitley EM; Chau GP; Lozano G; Wasylishen AR
Dis Model Mech; 2022 Aug; 15(8):. PubMed ID: 35976056
[TBL] [Abstract][Full Text] [Related]
14. Impact of tumor grade on pancreatic neuroendocrine tumors.
Shyr BS; Shyr BU; Chen SC; Shyr YM; Wang SE
Asian J Surg; 2022 Dec; 45(12):2659-2663. PubMed ID: 35246343
[TBL] [Abstract][Full Text] [Related]
15. Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression.
Saghafinia S; Homicsko K; Di Domenico A; Wullschleger S; Perren A; Marinoni I; Ciriello G; Michael IP; Hanahan D
Cancer Discov; 2021 Oct; 11(10):2638-2657. PubMed ID: 33910926
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
